Golden Green’s Adial Pharmaceuticals ADIL Stock Holding History

Golden Green’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-40	Closed	-$63K	–	145
2021 Q2	$63K	Buy	+40	New	+$60.8K	0.05%	150

Other funds holding ADIL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Golden Green's ADIL Position: Q3 2021 in Review

Golden Green sold out of Adial Pharmaceuticals (ADIL) in Q3 2021, closing a stake of 40 shares — an estimated $63K sold.

Golden Green first reported a position in ADIL in Q2 2021 and held it in 1 quarter. The position peaked at $63K in Q2 2021. 19 funds tracked by Wall St. Rank hold ADIL as of Q3 2021.

Golden Green reported no remaining Adial Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Golden Green sold 40 Adial Pharmaceuticals shares in Q3 2021, an estimated $63K.
Golden Green first reported a position in Adial Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Golden Green's Adial Pharmaceuticals position peaked at $63K in Q2 2021.
19 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q3 2021.

Based on Golden Green's 13F filing for Q3 2021, filed 8 Oct 2021.